03:08 PM EST - Acerus Pharmaceuticals Corporation : Reported that Health Canada has granted a Notice of Compliance for a generic version of ESTRACE®. As far as the Company is aware, the product is currently not available on the Canadian market. Acerus is closely monitoring the situation and evaluating the possible impact, if any, that a potential launch could have on ESTRACE® sales going forward. Acerus Pharmaceuticals Corporation
shares T.ASP are trading down $0.03 at $0.14.
